Market closed
Candel Therapeutics/$CADL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Candel Therapeutics
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Ticker
$CADL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
38
ISIN
US1374041093
Website
CADL Metrics
BasicAdvanced
$237M
-
-$1.74
-1.28
-
Price and volume
Market cap
$237M
Beta
-1.28
52-week high
$9.13
52-week low
$4.25
Average daily volume
962K
Financial strength
Current ratio
2.766
Quick ratio
2.735
Long term debt to equity
4.538
Total debt to equity
20.31
Interest coverage (TTM)
-15.61%
Management effectiveness
Return on assets (TTM)
-27.55%
Return on equity (TTM)
-139.56%
Valuation
Price to book
3.39
Price to tangible book (TTM)
3.39
Price to free cash flow (TTM)
-5.635
Growth
Earnings per share change (TTM)
32.86%
3-year earnings per share growth (CAGR)
-3.09%
CADL News
AllArticlesVideos
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewsWire·19 minutes ago
Candel Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire·1 week ago
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Candel Therapeutics stock?
Candel Therapeutics (CADL) has a market cap of $237M as of May 13, 2025.
What is the P/E ratio for Candel Therapeutics stock?
The price to earnings (P/E) ratio for Candel Therapeutics (CADL) stock is 0 as of May 13, 2025.
Does Candel Therapeutics stock pay dividends?
No, Candel Therapeutics (CADL) stock does not pay dividends to its shareholders as of May 13, 2025.
When is the next Candel Therapeutics dividend payment date?
Candel Therapeutics (CADL) stock does not pay dividends to its shareholders.
What is the beta indicator for Candel Therapeutics?
Candel Therapeutics (CADL) has a beta rating of -1.28. This means that it has an inverse relation to market volatility.